Product Description
Long-Acting GHRH Research Peptide
CJC-1295 with DAC is a synthetic peptide designed to mimic the activity of growth hormone-releasing hormone, or GHRH. It is studied for its ability to bind GHRH receptors at the pituitary gland and stimulate growth hormone release, which can subsequently influence insulin-like growth factor 1, or IGF-1, signaling.
The distinguishing feature of this compound is its Drug Affinity Complex, or DAC. This chemical modification is designed to increase binding to circulating albumin, substantially extending systemic exposure compared with non-DAC versions of CJC-1295.
CJC-1295 with DAC is associated with an extended research half-life of approximately 6 to 8 days. This prolonged activity makes it useful for models examining sustained endocrine signaling rather than the short-duration, pulsatile patterns associated with CJC-1295 without DAC, also known as Mod GRF 1-29.
Experimental research examines prolonged GH and IGF-1 activity in relation to body composition, lipid metabolism, visceral-fat signaling, protein synthesis, lean-mass pathways, tissue repair, exercise recovery, joint-related tissue models, and sleep-associated endocrine activity.
Key Research Areas
🧬
GHRH receptor and pituitary GH-axis signaling in laboratory models examining endogenous growth hormone release and endocrine regulation
🔗
Drug Affinity Complex and albumin binding in research examining prolonged systemic exposure and extended peptide activity
⏳
Long-duration GH signaling in models evaluating sustained pathway activity over an approximate 6–8 day half-life
📈
IGF-1 signaling following GH-axis stimulation and prolonged endocrine-pathway activation
🔥
Fat metabolism and body-composition pathways in research involving lipid breakdown, metabolic activity, overall fat mass, and visceral-adipose signaling
💪
Lean-mass and protein-synthesis signaling in models examining anabolic pathways, muscle-related tissue, strength-associated markers, and body composition
🛠️
Tissue repair and recovery in experimental models involving exercise stress, healing pathways, connective tissue, and joint-associated structures
🌙
Sleep-related endocrine signaling in research examining GH-axis activity alongside deep and restorative sleep-associated pathways
🔄
Sustained versus pulsatile GH activity in comparative models examining DAC-modified CJC-1295 against short-acting Mod GRF 1-29
This 5 mg presentation supports controlled long-duration GH-axis research designs, making it suitable for investigations across GHRH receptor signaling, albumin binding, extended peptide exposure, sustained growth hormone and IGF-1 activity, fat metabolism, visceral-adipose pathways, lean-mass signaling, protein synthesis, tissue repair, recovery, joint-related tissue, and sleep-associated endocrine pathways.
Intended Use
📦 Format: Lyophilized powder (5mg)
🧬 Compound: CJC-1295 with Drug Affinity Complex (DAC)
⚠️ Use: For laboratory research use only. Not for human or veterinary use.
Why Researchers Choose This Compound
⏳
Extended signaling profile supports investigation of prolonged GH-axis activity across multi-day research windows rather than short-duration signaling alone.
🔗
DAC-mediated albumin binding provides a distinct research framework for examining how molecular modifications can extend circulating peptide exposure.
📈
Combined GH and IGF-1 pathway relevance makes it useful for studying sustained endocrine signaling, anabolic pathways, metabolism, and tissue recovery.
🔥
Broad body-composition research utility offers a controlled framework for investigating fat metabolism, visceral-adipose signaling, protein synthesis, and lean-mass pathways.
🔄
Distinct comparison with No DAC formulations supports research contrasting sustained GH elevation with the shorter, more pulsatile activity profile of Mod GRF 1-29.
Product Notes
✅ Research category: GHRH, growth hormone, IGF-1, and long-duration endocrine signaling
✅ Study context: Laboratory and non-clinical research models
✅ Modification: Drug Affinity Complex (DAC) designed to support albumin binding and prolonged systemic exposure
✅ Activity profile: Long-acting, with an approximate 6–8 day research half-life
✅ Endocrine focus: GHRH receptor activation, pituitary GH release, sustained GH elevation, and downstream IGF-1 signaling
✅ Metabolic focus: Lipid metabolism, visceral-fat signaling, metabolic activity, and body-composition pathways
✅ Recovery focus: Protein synthesis, lean-mass pathways, connective-tissue research, recovery, and joint-associated tissue signaling
✅ Comparison focus: Sustained DAC-modified signaling versus the short-duration, pulsatile profile of CJC-1295 No DAC / Mod GRF 1-29
